摘要
肛管鳞癌(ASCC)是一种罕见的恶性肿瘤,大约90%的患者可归因于人乳头瘤病毒(HPV)感染。随着发病率和死亡率的逐年上升,关于ASCC的治疗方案也在不断探索。目前,局部进展期ASCC的标准治疗为放化疗,复发性或转移性ASCC目前仍采取含铂联合方案化疗作为标准治疗。随着包括放化疗、靶向治疗、免疫治疗和基于生物标志物的治疗在内的新型联合治疗策略的出现,ASCC的治疗策略也在不断改进。文章综述了局部进展期和转移性ASCC的诊疗进展,以期为临床诊疗提供参考意见。
Anal squamous cell carcinoma(ASCC)is a rare malignant tumor,with approximately 90%of patients attributed to human papilloma virus(HPV)infection.With the increase of incidence rate and mortality year by year,treatment options for ASCC are constantly being explored.At present,the standard treatment for locally advanced ASCC is chemoradiotherapy,while platinum containing combination chemotherapy is still used as the standard treatment for recurrent or metastatic ASCC.With the emergence of new combination strategies including chemoradiotherapy,targeted therapy,immunotherapy,and biomarker based therapy,the therapeutic prospects of ASCC are also rapidly developing.The article reviews the diagnostic and therapeutic progress of locally advanced and metastatic ASCC,in order to provide reference for clinical diagnosis and treatment.
作者
马晓婷
王晰程
巴一
Ma Xiaoting;Wang Xicheng;Ba Yi(Cancer Medical Center,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国肿瘤临床与康复》
2024年第5期296-305,共10页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
中国医学科学院医学与健康科技创新工程(2023-I2M-3-012)。
关键词
肛管鳞癌
人乳头瘤病毒
放化疗
免疫治疗
Anal squamous cell carcinoma
Human papilloma virus
Chemoradiotherapy
Immunotherapy
